Medicamen Biotech Limited · MEDICAMEQ

Every Medicamen Biotech Limited result whose ten-session window has closed, judged against the last read made before it. Open a result for the full account: the read, the sessions after, the reported figures, and every morning's read that led up to it. The company's own page →

19results judged

0read right

0read wrong

0flat / no call

19unread

21%beat the market

-1.8%avg vs market, 10d

4.3%avg move, T+1

How the reads on it fared

Read	Judged	Right	Wrong	Flat	Hit rate	Avg vs mkt
unread	19	0	0	0	—	-1.8%

A company that is often read strong and often proves it is one the model understands; one that is read strong and keeps lagging is where the model is wrong about a name, and this table is where that shows first.

Reading the rows

T+1: the share's move on the first session after the result, from the close before it
T+10: the move over ten sessions, same base
vs market: T+10 less NIFTY 50's move over the same ten sessions — the number every read is judged on
Run-up: the share's move in the thirty sessions before the result
Result: reported profit growth against the company's own last four quarters: good, in line, bad

Each result

19 judged · newest first · open one

Result	Read	Outcome	T+1	T+10	vs market	Run-up	Result	Why
14 Aug Q1FY27	—	unread	-6.1%	+8.7%	+9.9%	-8%	no figures	No reported figures on file for this quarter, so the result itself could not be judged. No read was made before this result; recorded for the base rate.	›
13 Feb Q3FY26	—	unread	-7.7%	-16.3%	-13.9%	-7%	no figures	No reported figures on file for this quarter, so the result itself could not be judged. No read was made before this result; recorded for the base rate.	›
14 Nov Q2FY26	—	unread	-2.6%	-2.2%	-3.2%	+39%	no figures	Ran up 39% in the 30 sessions before the result — a good number had little left to reward. No reported figures on file for this quarter, so the result itself could not be judged. 2 more	›
12 Aug Q1FY26	—	unread	-1.6%	-3.8%	-3.5%	-13%	no figures	No reported figures on file for this quarter, so the result itself could not be judged. Went into the result within 5% of its 52-week low. 1 more	›
30 May Q4FY25	—	unread	+1.9%	-4.3%	-5.1%	-12%	no figures	No reported figures on file for this quarter, so the result itself could not be judged. Delivery share rose 12 points in the fortnight before — someone was taking stock home. 1 more	›
11 Feb Q3FY25	—	unread	-1.1%	+10.6%	+12.9%	-7%	no figures	No reported figures on file for this quarter, so the result itself could not be judged. Delivery share rose 6 points in the fortnight before — someone was taking stock home. 1 more	›
15 Nov Q2FY25	—	unread	-1.9%	-2.1%	-5.3%	-21%	no figures	Fell 21% in the 30 sessions before the result — expectations were already low. The market itself moved +3.2% over the same ten sessions; the raw move is mostly tide. 4 more	›
13 Aug Q1FY25	—	unread	-4.9%	+1.3%	-1.6%	-11%	no figures	No reported figures on file for this quarter, so the result itself could not be judged. Announced during market hours, so the reaction session is the announcement day itself. 1 more	›
29 May Q4FY24	—	unread	-1.3%	-6.2%	-9.3%	+18%	no figures	Ran up 18% in the 30 sessions before the result — a good number had little left to reward. The market itself moved +3.1% over the same ten sessions; the raw move is mostly tide. 3 more	›
12 Feb Q3FY24	—	unread	+7.2%	+1.2%	-1.4%	-19%	no figures	Fell 19% in the 30 sessions before the result — expectations were already low. No reported figures on file for this quarter, so the result itself could not be judged. 2 more	›
10 Nov Q2FY24	—	unread	-2.3%	-3.4%	-6.9%	+1%	no figures	The market itself moved +3.5% over the same ten sessions; the raw move is mostly tide. No reported figures on file for this quarter, so the result itself could not be judged. 2 more	›
8 Aug Q1FY24	—	unread	-1.2%	-10.1%	-9.3%	+22%	no figures	Ran up 22% in the 30 sessions before the result — a good number had little left to reward. No reported figures on file for this quarter, so the result itself could not be judged. 2 more	›
31 May Q4FY23	—	unread	-2.6%	-5.3%	-5.7%	-2%	no figures	No reported figures on file for this quarter, so the result itself could not be judged. Announced during market hours, so the reaction session is the announcement day itself. 1 more	›
10 Feb Q3FY23	—	unread	-5.3%	-14.2%	-11.6%	-9%	no figures	No reported figures on file for this quarter, so the result itself could not be judged. No read was made before this result; recorded for the base rate.	›
11 Nov Q2FY23	—	unread	-6.1%	-5.5%	-6.7%	-9%	no figures	No reported figures on file for this quarter, so the result itself could not be judged. Delivery share rose 7 points in the fortnight before — someone was taking stock home. 1 more	›
10 Aug Q1FY23	—	unread	-0.9%	+48.0%	+47.8%	+7%	no figures	No reported figures on file for this quarter, so the result itself could not be judged. Volume ran 3.2x its prior month in the fortnight before. 1 more	›
25 May Q4FY22	—	unread	+3.8%	+8.9%	+6.1%	-24%	no figures	Fell 24% in the 30 sessions before the result — expectations were already low. No reported figures on file for this quarter, so the result itself could not be judged. 1 more	›
8 Feb Q3FY22	—	unread	-9.4%	-27.0%	-25.8%	-14%	no figures	No reported figures on file for this quarter, so the result itself could not be judged. No read was made before this result; recorded for the base rate.	›
3 Nov Q2FY22	—	unread	+14.6%	-3.3%	-1.0%	—	no figures	No reported figures on file for this quarter, so the result itself could not be judged. Went into the result within 3% of its 52-week high. 1 more	›